|
Home:
Educational
Supplement: Section 6
SELECT PUBLICATIONS
Brunner N et
al. MCF7/LCC9: An antiestrogen-resistant MCF-7 variant in which
acquired resistance to the steroidal antiestrogen ICI 182,780 confers
an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Cancer Res 1997;57:3486-93. Abstract
Bundred N et
al. ICI 182,780 (Faslodex) an estrogen receptor downregulator,
reduces cell turnover index more effectively than tamoxifen.
Proc ASCO 2001;Abstract
1660.
Carroll JS et
al. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity
in MCF-7 breast cancer cells and induces accumulation of p130-E2F4
complexes characteristic of quiescence. J Biol Chem 2000;275:38221-9.
Abstract
Curran M, Wiseman
L. Fulvestrant. Drugs 2001;61:807-13; discussion 814.
Abstract
Cicatiello
L et al. The antiestrogen ICI 182,780 inhibits proliferation
of human breast cancer cells by interfering with multiple, sequential
estrogen-regulated processes required for cell cycle completion.
Mol Cell Endocrinol 2000;165:199-209. Abstract
Diel P et al.
Treatment with the Pure Antiestrogen Faslodex (ICI 182780) Increases
the Sensitivity of MCF-7 Breast Cancer Cells against Fas Induced
Apoptosis. Breast Ca Res Treat 2000;Abstract
376.
Diel P et al.
The pure antiestrogen ICI 182780 is more effective in the induction
of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7
cells. Breast Cancer Res Treat 1999;58:87-97. Abstract
Ellis PA et
al. Induction of apoptosis by tamoxifen and ICI 182780 in primary
breast cancer. Int J Cancer 1997;72:608-13. Abstract
England GM,
Jordan VC. Pure antiestrogens as a new therapy for breast cancer.
Oncol Res 1997;9:397-402. Abstract
Erikstein B
et al. ICI 182,780 ('Faslodex') 250 mg monthly intramuscular
(i.m.) injection shows consistent pk profile when given as either
1 x 5ml or 2 x 2.5 ml injections in postmenopausal women with advanced
breast cancer (ABC). Proc ASCO 2001; Abstract
2025.
Gradishar WJ,
Jordan VC. Clinical potential of new antiestrogens. J
Clin Oncol 1997;15:840-52. Abstract
Hilakivi-Clarke
L et al. Alterations in mammary gland development following neonatal
exposure to estradiol, transforming growth factor alpha, and estrogen
receptor antagonist ICI 182,780. J Cell Physiol 1997;170:279-89.
Abstract
Howell A et
al. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant
breast cancer. Lancet 1995;345:29-30. Abstract
Howell A. Faslodex
(ICI 182780). An oestrogen receptor downregulator. Eur J
Cancer. 2000;36 Suppl 4:S87-8. Abstract
Howell A et
al. ICI 182,780 (Faslodex): Development of a novel, "pure"
antiestrogen. Cancer 2000;89(4):817-825. Abstract
Howell A et
al. Comparison of efficacy and tolerability of fulvestrant (Faslodex)
with anastrozole (Arimidex) in post-menopausal women with advanced
breast cancer. Breast Ca Res Treat 2000;64(1):Abstract
6.
Howell A et
al. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant
breast cancer. Lancet 1995;345:29-30. Abstract
Howell A et
al. Pharmacokinetics, pharmacological and anti-tumour effects
of the specific antioestrogen ICI 182780 in women with advanced
breast cancer. Br J Cancer 1996;74:300-8. Abstract
Kurebayashi
J et al. A pure antiestrogen, ICI 182,780, stimulates the growth
of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but
not in vitro. Oncology 1998;55 Suppl 1:23-34. Abstract
Larsen SS et
al. Resistance of human breast-cancer cells to the pure steroidal
anti-estrogen ICI 182,780 is not associated with a general loss
of estrogen-receptor expression or lack of estrogen responsiveness.
Int J Cancer 1997;72:1129-36. Abstract
Lee ES, Schafer
JM, Yao K et al. Cross-resistance of triphenylethylene-type antiestrogens
but not ICI 182,780 in tamoxifen-stimulated breast tumors grown
in athymic mice. Clin Cancer Res 2000;6:4893-9. Abstract
Long BJ et
al. The steroidal antiestrogen ICI 182,780 is an inhibitor of
cellular aromatase activity. J Steroid Biochem Mol Biol 1998;67:293-
304. Abstract
McClelland
RA et al. Enhanced epidermal growth factor receptor signaling
in MCF7 breast cancer cells after long-term culture in the presence
of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology
2001;142:2776-88. Abstract
McClelland
RA et al. Short-term effects of pure anti-oestrogen ICI 182780
treatment on oestrogen receptor, epidermal growth factor receptor
and transforming growth factor-alpha protein expression in human
breast cancer. Eur J Cancer 1996;32A:413-6. Abstract
McLeskey SW
et al. Tamoxifen-resistant fibroblast growth factor-transfected
MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI
182,780 and two aromatase inhibitors. Clin Cancer Res 1998;4:697-711.
Abstract
Nawaz Z et
al. The pure antiestrogen ICI 182,780 inhibits progestin-induced
transcription. Cancer Res 1999;59:372-6. Abstract
Osborne CK.
A double-blind randomized trial comparing the efficacy and tolerability
of FaslodexTM (fulvestrant) with ArimidexTM (anastrozole) in post-menopausal
(PM) women with advanced breast cancer (ABC). Breast Ca Res
Treat 2000;64(1): Abstract
7.
Osborne CK et
al. Selective estrogen receptor modulators: Structure, function
and clinical use. J Clin Oncol 2000;18(17):3172-3186.
Abstract
O'Regan RM
et al. Effects of the antiestrogens tamoxifen, toremifene, and
ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst
1998;90:1552-8. Abstract
Parisot JP
et al. Induction of insulin-like growth factor binding protein
expression by ICI 182,780 in a tamoxifen-resistant human breast
cancer cell line. Breast Cancer Res Treat 1999;55:231-42.
Abstract
Robertson JFR.
A comparison of the single-dose pharmacokinetics (PK) of 'Faslodex'
(fulvestrant) 250 mg when given as either a one x 5-ml intramuscular
(i.m.) injection or two x 2.5-ml injections in postmenopausal (PM)
women with advanced breast cancer (ABC). Breast Ca Res Treat
2000;Abstract
172.
Robertson JFR
et al. Duration of remission to ICI 182,780 compared to megestrol
acetate in tamoxifen-resistant breast cancer. Breast 1997;6:186-9.
No Abstract Available
Rosenberg Z
et al. Is ICI 182,780 an antiprogestin in addition to being an
antiestrogen? Breast Cancer Res Treat. 2000;60:1-8. Abstract
Salerno M et
al. Insulin receptor substrate 1 is a target for the pure antiestrogen
ICI 182,780 in breast cancer cells. Int J Cancer 1999;81:299-304.
Abstract
Smolnikar K
et al. Treatment with the pure antiestrogen Faslodex (ICI 182780)
induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7
breast cancer cells. Breast Cancer Res Treat
2000;63:249-59. Abstract
Top
Additional
Sections:
1 | 2
| 3 | 4
| 5 | 6
| 7 | 8
| 9 | 10
| 11 | 12
|
|
